Cargando…

A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer

Purpose SM-88 (D,L-alpha-metyrosine; racemetyrosine) is a novel anti-cancer agent, used with melanin, phenytoin, and sirolimus (SMK Therapy). This pilot first-in-human study characterized the safety, tolerability, and efficacy of SMK Therapy in subjects with advanced metastatic cancer. Methods All s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stega, Jeanetta, Noel, Marcus S., Vandell, Alexander G., Stega, Damian, Del Priore, Giuseppe, Hoffman, Steve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Phase I Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066285/ https://www.ncbi.nlm.nih.gov/pubmed/30929156 http://dx.doi.org/10.1007/s10637-019-00758-8

Ejemplares similares

Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer
por: Gartrell, Benjamin A., et al.
Publicado: (2020)

Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer
por: Boku, Narikazu, et al.
Publicado: (2013)

A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2012)

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
por: Soto, Elena, et al.
Publicado: (2010)

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
por: Noel, Marcus, et al.
Publicado: (2019)

ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer
por: Crabb, Simon J., et al.
Publicado: (2017)

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
por: Davis, S. Lindsey, et al.
Publicado: (2019)

Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer
por: Komatsu, Yoshito, et al.
Publicado: (2013)

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
por: Takahashi, Shunji, et al.
Publicado: (2019)

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
por: Beumer, J. H., et al.
Publicado: (2007)

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents
por: Zandvliet, Anthe S., et al.
Publicado: (2009)

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
por: Moschos, Stergios J., et al.
Publicado: (2022)

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
por: Bhatia, Shailender, et al.
Publicado: (2016)

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
por: Awada, Ahmad, et al.
Publicado: (2015)

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
por: Even, C., et al.
Publicado: (2019)

Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses
por: Uhl, Wolfgang, et al.
Publicado: (2013)

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
por: von Mehren, Margaret, et al.
Publicado: (2014)

First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects
por: Wang, Meng-na, et al.
Publicado: (2020)

Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study
por: Gupta, Neeraj, et al.
Publicado: (2016)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

A phase Ib study of everolimus combined with metformin for patients with advanced cancer
por: Molenaar, Remco J., et al.
Publicado: (2017)

Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer
por: Roosendaal, Jeroen, et al.
Publicado: (2019)

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects
por: Halstenson, C. E., et al.
Publicado: (2016)

Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics
por: Nwankwo, Nwabundo, et al.
Publicado: (2012)

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
por: van der Noll, R., et al.
Publicado: (2015)

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2015)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2011)

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer
por: Goldman, Jonathan W., et al.
Publicado: (2017)

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
por: Goff, Laura W., et al.
Publicado: (2016)

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer
por: Horinouchi, Hidehito, et al.
Publicado: (2015)

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer
por: Okamoto, Isamu, et al.
Publicado: (2009)

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer
por: Pili, Roberto, et al.
Publicado: (2014)

A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1)
por: Sato, Takeo, et al.
Publicado: (2016)

Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study
por: Lozanovski, Vladimir J., et al.
Publicado: (2019)

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study
por: Olmedo, María Eugenia, et al.
Publicado: (2021)

A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer
por: Kordes, Sil, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nq6gl8cdr4d9nuggihjjbfma60